


MIRTAZAPINE
ZISPIN 30 mg
The NaSSA


Strong
yet
gentle

in

depression



...when it's more than just depression



- Superior Efficacy in the Treatment of Depression with Anxiety¹
- Benign Side Effect Profile in Adults and Elderly²
- Highly Flexible, Once Daily Dosage^{3,4}

SEROXAT
paroxetine

...takes the anxiety out of treating depression

'SEROXAT' Abbreviated Irish Prescribing Information. Presentation: 'Seroxat' Tablets, PA 49/50/1-2, each containing either 20 mg or 30 mg paroxetine as the hydrochloride and 'Seroxat' Liquid, PA 49/50/1-2, each containing 20 mg/10ml paroxetine as the hydrochloride. **Uses:** Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Prevention of relapse and also recurrence of further depressive episodes. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms of panic disorder with or without agoraphobia. **Dosage:** Adults: Depression: 20 mg daily and if necessary increase dose by 10 mg increments to a maximum of 50 mg according to response. Obsessive compulsive disorder and panic disorder: 40 mg daily. Start on 20 mg daily and increase weekly in 10 mg increments to a maximum of 60 mg daily according to response. Possible worsening of panic symptoms during early treatment of panic disorder is generally recognised, thus low initial starting dose is recommended. Dosage should be reviewed and adjusted if necessary within two to three weeks of initiation of therapy and thereafter as judged clinically appropriate. Continue treatment for a sufficient period, which may be several months for depression and possibly longer for OCD and panic disorder. Abrupt discontinuation should be avoided. Elderly: 20 mg daily increasing by increments of 10 mg to 40 mg daily according to response. Children: Not recommended. Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment: 20 mg daily. Restrict incremental dosage if required to lower end of range. **Contra-indications:** Hypersensitivity to paroxetine and related drugs; use with MAO inhibitors; unstable epilepsy or convulsant disorders; severe renal failure. **Precautions:** History of mania. Cardiac conditions, use with ECT: caution. Caution in patients with controlled epilepsy (monitor carefully) Stop treatment if seizures develop. Caution patients about driving and operating machinery. **Drug interactions:** Do not use within two weeks after stopping MAO inhibitors; leave a two-week gap between stopping 'Seroxat' and before starting MAO inhibitor treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Consider using lower doses if given with drug metabolising enzyme inhibitors; adjust 'Seroxat' dosage if necessary when given with drug metabolising enzyme inducers. Combination with other highly bound protein drugs may alter plasma levels of either. Alcohol is not advised. Caution with other CNS active drugs. Keep dosage of concomitant benzodiazepines to a minimum. Use concurrent lithium administration with caution and monitor lithium levels. Increased adverse events with phenytoin; similar possibility with other anticonvulsants. **Pregnancy and lactation:** Use in pregnancy only if essential and avoid during lactation. **Adverse reactions:** Most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (impotence and abnormal ejaculation), dizziness, constipation, diarrhoea, decreased appetite. Spontaneous reports of dizziness, headache, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash. As with other SSRIs, symptoms suggestive of postural hypotension, hypotension, hypertension, tachycardia. Also other arrhythmias (rare). Extrapyramidal reactions, rarely hyponatraemia (possible SIADH), liver function abnormality. Abrupt discontinuation may cause dizziness, sensory disturbance, agitation or anxiety, nausea and sweating. **Product authorisation holder:** SmithKline Beecham Pharmaceuticals Ltd, Corrig Avenue, Dun Laoghaire, Dublin. **Further information is available from this address.** Telephone: 01-284 5555. October 1998. 'Seroxat' is a trade mark.